TrkB neurotrophin receptor as a drug target

Description of the granted funding

Neuronal plasticity is critical for learning and memory, but also for the antidepressant drug action. We recently found that essentially all antidepressants act by directly binding to TrkB, the receptor for brain-derived neurotrophic factor (BDNF) and enhancing BDNF signalling and neuroplasticity. As certain serotonin receptor agonists have been reported to produce long-lasting antidepressant effects, we will here study whether these serotonin agonists and serotonin itself might bind to TrkB and promote BDNF signalling. We will reveal the detailed structure of the binding site in TrkB and study whether the antidepressant and plasticity-promoting effects of these drugs are mediated by TrkB. We will then search for novel compounds that bind to TrkB with high affinity and selectivity. We believe that these selective high-affinity TrkB ligands could become the next generation antidepressant and plasticity enhancing drugs, producing a paradigm shift in the drug treatment of depression.
Show more

Starting year

2022

End year

2026

Granted funding

Eero Castren Orcid -palvelun logo
500 000 €

Funder

Research Council of Finland

Funding instrument

Academy projects

Other information

Funding decision number

347358

Fields of science

Neurosciences

Research fields

Neurotiede

Identified topics

brain, neuroscience